Q&A session 4 for paid subscribers

How many people clear EBV from having AHSCT? ... Regarding anti-CD20 therapies, would you recommend ocrelizumab (Ocrevus) or ofatumumab (Kesimpta)?

Questions

Q1: How many people clear EBV from having AHSCT?

Q2: Could two doses of chemo post stem cell collection (AHSCT) be enough to wipe B and T cell memory, followed by an anti-CD20 a week later? 

Q3: Regarding anti-CD20 therapies, would you recommend ocrelizumab (Ocrevus) or ofatumumab (Kesimpta)? 

NOTE: General substack newsletters and microsite are free; it is only Q&A sessions that are restricted to paying subscribers. I can't run and maintain the MS-Selfie microsite, hence the need to pay people to help do the work for me. If people want to ask medical questions unrelated to the Newsletters or Podcasts, they either need to become paying subscribers or email (ms-selfie@giovannoni.net) to request a complimentary subscription.